Real-World study tracks Benralizumab's impact on severe asthma in china
NCT ID NCT06862206
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study follows 1,000 people aged 12 and older in China who have severe eosinophilic asthma and are prescribed benralizumab. Researchers will track how well the drug controls asthma symptoms over time using questionnaires, and note reasons for stopping or switching treatment. The goal is to understand how benralizumab works in everyday medical practice, not in a controlled lab setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- benralizumab
- What this could lead to
- If successful, this study could provide real-world evidence on how well benralizumab controls severe asthma in Chinese patients, helping doctors tailor treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment or prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAnhui, China
-
Research Site
RECRUITINGAnning, China
-
Research Site
RECRUITINGBeijing, China
-
Research Site
RECRUITINGBinzhou, China
-
Research Site
RECRUITINGChangzhou, China
-
Research Site
RECRUITINGFenyang, China
-
Research Site
RECRUITINGGuangdong, China
-
Research Site
RECRUITINGGuangzhou, China
-
Research Site
RECRUITINGHangzhou, China
-
Research Site
RECRUITINGHuzhou, China
-
Research Site
RECRUITINGJiaxing, China
-
Research Site
RECRUITINGJinan, China
-
Research Site
RECRUITINGJinhua, China
-
Research Site
RECRUITINGJining, China
-
Research Site
RECRUITINGJiyuan, China
-
Research Site
RECRUITINGKunshan, China
-
Research Site
RECRUITINGLinyi, China
-
Research Site
RECRUITINGMianyang, China
-
Research Site
RECRUITINGNanbu, China
-
Research Site
RECRUITINGNanchang, China
-
Research Site
RECRUITINGNanjing, China
-
Research Site
RECRUITINGNingbo, China
-
Research Site
RECRUITINGShanghai, China
-
Research Site
RECRUITINGShanxi, China
-
Research Site
RECRUITINGShenzhen, China
-
Research Site
RECRUITINGShijiazhuang, China
-
Research Site
RECRUITINGSuining, China
-
Research Site
RECRUITINGTaiyuan, China
-
Research Site
RECRUITINGWeifang, China
-
Research Site
RECRUITINGWuhan, China
-
Research Site
RECRUITINGWuxi, China
-
Research Site
RECRUITINGXi'an, China
-
Research Site
RECRUITINGXiamen, China
-
Research Site
RECRUITINGZhangjiagang, China
-
Research Site
RECRUITINGZhengzhou, China
-
Research Site
RECRUITINGZhenjiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentle exercise with leg cuffs may offer a new path to rehab for COPD patients
- Could treating sleep apnea during a COPD hospital stay keep patients out of the hospital?
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
- HIV and lungs: botswana study seeks clues to COPD risk
- Ultrasound of the lungs may unmask hidden heart failure in COPD patients
- Could pedaling backward help heart and lung patients get stronger?